Skip to main content

Fosun, BioNTech Form $200 Million China JV to Make COVID-19 Vaccine

Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China . The JV will have capacity to manufacture 1 billion doses of the vaccine. Fosun will invest $100 million to build the facility for its 50% share of the JV, while BioNTech will contribute its proprietary manufacturing technology, which it values at $100 million. In March 2020, the two companies partnered China development of the COVID-19 vaccine in a $135 million deal. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.